Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DOC328...Thanks for the facts.
Let me ask about some AD context and the inevitable "so what" next step. Will this tool enable better assessment of treatment w/A2-73 (state assumptions) or is it too early to say.
Very much appreciate your insights and guidance on where this leads us in your opinion? My expectation is he will tie the links on how we are better off b/c of the PET facts.
Well said.
Turning base now...thanks
Still no bad news.
Good observation and I agree. On a positive note, we can be certain there REALLY is no science bad news. Considering the massive meltdown failures of BP AD attempts, if they had any evidence of AVXL being a Scientific dead end they would certainly be telling the world about it. So we got that going for us.
(You may recognize this line from an old Bill Murray movie (Caddy Shack).
Dado...we are in synch...I think I just set a new record for shortest life posted AVXL message. All the best. BTW, the frat boys do not seem to get the new process concept and it's consequences, they are stuck in trials take forever and there will be plenty of time to cover. NOT.
All the best.
OK, you guys take the point. Keep us in the loop...who knows, maybe it is good news for a change.
Nice...hope you are being TOO cautious and we are up more..thx...green s good
IMO, this note is a refreshing and honest statement of leadership. He is showing a type of open conference appeal not seen in regulatory speak in the past. This is as close to a mea culpa as we will get.
Guesses on today's SP action?
Will we be way up? Way down? Stable? How come?
I cannot see a clear =/- but want to see some good news....up by 0.50 at least.
Thanks for posting Dr. G. and FDA comments. Wow, who knew just how much of a leadership opportunity they have. Sounds like RWE uses and future trials will be an issue. Warehoused RWE data is not being effectively used, who Knew?
Maybe they read this from Corp presentation, May 2018...
[quoteLetting it run-up then "crushing" the price during AAIC will be much more profitable. ][/quote]
Understand that this is the conventional thinking. BUT...what if Anavex presents life changing results with undeniable evidence of efficacy? Do they who just run with the herd, take their cash and run or do they stay with the rest of us? First of all they have to be capable of understanding the evidence and it's impact. Then they have to be able to look certain risks and potential hazards in the eye and then THINK THEIR WAY THROUGH?
So, do they run with the herd and bail or stay on board and risk whatever happens next? IMO, that is how big this is.
This post is very well done. Thanks for the effort and thought.
Your post presents a reasonable philosophy but you may have missed the new definition of P3 pass/fail rules. Another point is the methods for selection of participants and the projections based on Biometrics have never been done before either. In other words, it is still tough but the game is not the same. In fact it is not even close.
Then there is this question on safety ref: gene therapy
https://www.marketwatch.com/story/gene-therapy-stocks-slammed-after-scientist-reveals-safety-concerns-2018-01-30
Sigma-1R helping / s2mula2ng own body to regain func2onality
It's alot of clues in this presentation.
here is part of the beauty of Anavex..
we are an adjunct to any and very treatment..
Sarepta tested its gene therapy, called micro-dystrophin, in Duchenne muscular dystrophy patients ages 4 to 7. Leerink analyst Joseph Schwartz called the data a "home run." On average, the three patients showed an 87% reduction of an enzyme tied to the disease by day 60.
3 boys who responded positively to their drug that addresses Duchenne muscular dystrophy were at the investor event).
Does anyone have an example of a biotech that has been a "test case" for an FDA initiative?
Never Mind...I found it.
Looks like NAS futures are down about 100 pts? Red Sox at Minn. later today. Anything else going on? Have a wonderful friggen day.
dynamic complexities of the human body that represent the still poorly understood bigger picture of how people stay well, get sick or get well.
Did our golfer start golfing again because of better cognition AND feeling stronger?
Did our painter and pianist have tremor of lack of strength and energy that contributed to their loss of skills in addition to cognitive issues? Did 2-73 help with both of those issues?
Is this the ICEBERG we are looking at?
Some things just take time I guess.
https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html
SSSSSHHHHHHHHus
This information suggests the knowledge pool at AVXL is very deep. Nice.